Can you provide the average price target for BIOVENTUS INC - A stock?
9 analysts have analysed BVS and the average price target is 14.89 USD. This implies a price increase of 64.37% is expected in the next year compared to the current price of 9.06.
NASDAQ:BVS • US09075A1088
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOVENTUS INC - A (BVS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-06 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-03-06 | Craig-Hallum | Maintains | Buy -> Buy |
| 2026-02-09 | Barrington Research | Initiate | Outperform |
| 2025-07-07 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-12-17 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-11-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-09-27 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-08-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-07 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-05-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-13 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-12-07 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2023-04-03 | Craig-Hallum | Maintains | Hold |
| 2022-11-30 | Goldman Sachs | Maintains | Neutral |
| 2022-11-22 | Craig-Hallum | Downgrade | Buy -> Hold |
| 2022-11-10 | Morgan Stanley | Maintains | Overweight |
| 2022-11-09 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2022-11-09 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-10-11 | Morgan Stanley | Maintains | Overweight |
| 2022-09-07 | Goldman Sachs | Maintains | Neutral |
| 2022-08-12 | Morgan Stanley | Maintains | Overweight |
| 2022-05-12 | Morgan Stanley | Maintains | Overweight |
| 2022-03-11 | Morgan Stanley | Maintains | Overweight |
| 2021-11-15 | Morgan Stanley | Reiterate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 512.345M 0.05% | 573.28M 11.89% | 568.087M -0.91% | 610.79M 7.52% | 653.91M 7.06% | 694.1M 6.15% | 737.07M 6.19% | 792.93M 7.58% | |
| EBITDA YoY % growth | 58.672M 397.22% | 70.957M 20.94% | 103.302M 45.58% | 122.21M 18.30% | 135.27M 10.69% | 152.19M 12.51% | 156.31M 2.71% | 177.09M 13.29% | |
| EBIT YoY % growth | 1.307M 102.38% | 21.402M 1,537.49% | 56.291M 163.02% | 93.554M 66.20% | 105.34M 12.60% | 109.77M 4.21% | N/A | N/A | |
| Operating Margin | 0.26% | 3.73% | 9.91% | 15.32% | 16.11% | 15.81% | N/A | N/A | |
| EPS YoY % growth | 0.00 -100.00% | 0.47 | 0.68 44.68% | 0.76 11.77% | 0.88 16.28% | 1.03 16.57% | 1.05 1.96% | 1.21 15.38% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.10 23.09% | 0.22 5.81% | 0.18 21.20% | 0.25 4.16% | 0.12 17.95% | 0.27 20.45% | 0.21 13.89% | 0.30 19.19% | 0.17 47.83% | 0.33 24.53% | 0.25 21.95% | 0.33 11.86% |
| Revenue Q2Q % growth | 131.15M 5.87% | 158.23M 7.16% | 150.36M 8.44% | 171.06M 8.33% | 139.53M 6.39% | 168.19M 6.29% | 158.95M 5.71% | 181.98M 6.38% | 149.28M 6.99% | 179.38M 6.65% | 169.98M 6.94% | 194.83M 7.06% |
| EBITDA Q2Q % growth | 21.188M 26.01% | 33.658M -20.40% | 29.404M -36.86% | 37.958M -44.77% | 22.802M 7.62% | 37.798M 12.30% | 31.671M 7.71% | 44.193M 16.43% | 27.068M 18.71% | 42.218M 11.69% | 34.643M 9.38% | 48.682M 10.16% |
| EBIT Q2Q % growth | 14.893M 200.87% | 25.847M 40.71% | 22.447M 99.51% | 30.402M 39.97% | 12.727M -14.54% | 27.672M 7.06% | 21.47M -4.35% | 33.942M 11.64% | 23.331M 83.32% | 38.481M 39.06% | 30.805M 43.48% | 44.945M 32.42% |
All data in USD
9 analysts have analysed BVS and the average price target is 14.89 USD. This implies a price increase of 64.37% is expected in the next year compared to the current price of 9.06.
BIOVENTUS INC - A (BVS) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of BIOVENTUS INC - A (BVS) is 0.1 USD and the consensus revenue estimate is 131.15M USD.
The consensus rating for BIOVENTUS INC - A (BVS) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.